Clinical TrialApr 23, 2026, 12:01 PM
Orchestra BioMed's AVIM Therapy Reduces SBP by 13.2 mmHg
AI Summary
Orchestra BioMed announced positive data from its MODERATO II trial for AVIM Therapy, demonstrating significant and sustained blood pressure reductions. The therapy achieved an immediate mean reduction of 13.2 mmHg in office systolic blood pressure, with 97% of patients showing a reduction greater than 5 mmHg. These results suggest AVIM Therapy's potential for sustained blood pressure control without reliance on additional medications, aligning with the ongoing BACKBEAT Global Pivotal Trial.
Key Highlights
- AVIM Therapy showed an immediate 13.2 mmHg reduction in office systolic blood pressure (oSBP).
- 97% of patients experienced an immediate oSBP reduction of >5 mmHg.
- At 6 months, 89% of patients achieved aSBP <140 mmHg; 58% achieved aSBP <130 mmHg.
- Sustained reductions in aSBP were observed through 3.6 years of follow-up in a sub-cohort.